MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


MyHealthChecked to sell Concepta Diagnostics and become cash shell

ALN

MyHealthChecked PLC on Tuesday announced it struck a deal to sell its trading subsidiary Concepta Diagnostics Ltd to retailer Boots UK Ltd for £2.4 million.

MyHealthChecked, a Cardiff-based home-testing healthcare products firm, will be a cash shell when the deal concludes.

‘Concepta distributes and commercialises a range of at-home healthcare and wellness tests and has developed an accompanying proprietary digital platform. The company has worked closely with Boots to develop its wellness portfolio and digital offering since its launch in May 2023 and has developed the platform to meet Boots’ requirements since the relationship began in May 2021,’ MyHealthChecked said.

MyHealthChecked said Concepta is likely to be loss-making for the foreseeable future, so a sale is in the best interests of shareholders.

Shareholders will vote on the disposal at a general meeting on November 4.

Chief Executive Officer Penny McCormick said: ‘During this past year, operational costs have not been offset by Covid sales, demand for which has declined significantly, and despite growth in the sales of wellness tests and tight cost controls, the loss for H1 of the current year has been broadly comparable to the prior year.’

She added: ‘We have regularly updated shareholders throughout the development of a longstanding working relationship with Boots, which has potential to be a significant player in the growth of home testing. As we look to the future, we have identified Boots as the right partner to take forward the MHC portfolio and drive home-testing as part of a wider range of healthcare services.’

MyHealthChecked shares dove 13% to 8.67 pence each on Tuesday afternoon in London.

Copyright 2025 Alliance News Ltd. All Rights Reserved.